𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Multimodal therapy before liver transplantation for hepatocellular carcinoma

✍ Scribed by Alessandro Vitale; Alberto Brolese; Giacomo Zanus; Marco Bassanello; Umberto Montin; Enrico Gringeri; Francesco D’Amico; Francesco Antonio Ciarleglio; Amedeo Carraro; Gianluca Cappuzzo; Alessio Bridda; Davide Francesco D’Amico; Umberto Cillo

Book ID
108138218
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
147 KB
Volume
31
Category
Article
ISSN
1386-6346

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatocellular carcinoma: Sorafenib befo
Hepatocellular carcinoma: Sorafenib before liver transplantation?
✍ Alain Braillon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 1 views

This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocio´n Cien-tı´fica y Tecnolo´gica).

Neoadjuvant therapies for hepatocellular
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: A critical appraisal
✍ Patricia M. Lopez; Augusto Villanueva; Sasan Roayaie; Josep M. Llovet 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

Hepatocellular carcinoma (HCC) is a major health problem, being the fifth most common cancer worldwide. 1 The incidence of HCC is increasing in Europe and the United States, 2 and it is currently the leading cause of death among patients with cirrhosis. 3 The advent of surveillance programs has led

Sorafenib therapy in patients with hepat
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation
✍ Ian A. Rowe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

The team of Liu et al. generated endoderm-derived human induced pluripotent stem (iPS) cells from primary hepatocytes. 1 However, they generated human iPS cells by using viral transgenes. 1 Clinical applications of human iPS cells require avoiding viral transgenes. On the other hand, the reprogrammi